SNA™ Gene Regulation Therapeutics

Learn More

About Us

AuraSense Therapeutics is a biopharmaceutical company developing first-in-class therapies based on Spherical Nucleic Acid (SNA™) gene regulation strategies. AST is leading the translation of SNA constructs as innovative medicines with a core focus on debilitating diseases. AuraSense Therapeutics' uniquely engineered SNA™ constructs possess unparalleled biocompatibility and versatility as therapeutics. They hold great promise for combating the most threatening diseases, including cancer, skin conditions and infection.

SNA™ constructs overcome one of the most difficult obstacles to gene regulation:  safe and effective delivery into cells and tissues.  SNA™ constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutics for the treatment of cancer or infectious disease.

SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology.  The Company's scientific founders and their developments have been the subject of over 80 national and international awards, over 550 publications, and over 940 patents and applications (247 issued). AuraSense Therapeutics is a subsidiary of AuraSense, LLC.

Latest News

  • Bill Gates among new backers of Skokie startup

    June 20, 2014go

  • AuraSense Therapeutics Completes $13.6 Million Series C Equity Investment

    June 17, 2014go

  • New System for Treating Cancer Seen as Hopeful

    June 2, 2014go

  • What On Earth Is This Thing And How Exactly Can It Help Me?

    March 28, 2014go

  • How Doctors Are Harnessing the Power of Gold to Fight Cancer

    February 19, 2014go